natgillin/translations-raw huggingface dataset:
REYATAZ/ritonavir-armen viste antiviral effekt svarende til lopinavir/ritonavir-armen (non-inferiør) vurderet ved andelen af patienter med hiv-RNA <50 kopier/ml ved uge 48: 78% af patienterne, der fik REYATAZ/ritonavir sammenligner med 76%, der fik lopinavir/ritonavir (estimeret forskel på ATV/RTV-LPV/RTV: 1,7% [95% CI, -3,8%; 7,1%] ifølge bekræftet virologisk respons (Confirmed Virologic Response - CVR) non-completer = Svigt (NC = F) definition af respons. 
The REYATAZ/ritonavir arm has similar (non-inferior) antiviral efficacy compared to the lopinavir/ritonavir arm, as assessed by the proportion of patients with HIV RNA < 50 copies/ml at week 48: 78% of patients on REYATAZ/ritonavir compared to 76% on lopinavir/ritonavir (difference estimate of ATV/RTV-LPV/RTV: 1.7% [95% CI, -3.8%, 7.1%] according to the Confirmed Virologic Response (CVR) Non-Completer = Failure (NC = F) definition of response.
Patienter i behandling med REYATAZ, som har forhøjede levertransaminaser og forhøjet bilirubin samtidig, bør evalueres for alternative ætiologier. 
Hepatic transaminase elevations that occur with elevated bilirubin in patients receiving REYATAZ should be evaluated for alternative aetiologies.
De farmakokinetiske data fra hiv-smittede gravide kvinder, der fik REYATAZ kapsler med ritonavir, er beskrevet i Tabel 9. 
The pharmacokinetic data from HIV-infected pregnant women receiving REYATAZ capsules with ritonavir are presented in Table 9.
Koncentrationerne af atazanavir med eller uden ritonavir forventes at øges hos patienter med moderat eller alvorligt nedsat leverfunktion (se pkt. 
Concentrations of atazanavir with or without ritonavir are expected to be increased in patients with moderately or severely impaired hepatic function (see sections 4.2, 4.3, and 4.4).
Ved AT-analyse, hvor manglende værdier blev ekskluderet, var andelen af patienter med hiv-RNA <400 kopier/ml (<50 kopier/ml) for REYATAZ+ ritonavir 84% (72%) og for lopinavir + ritonavir 82% (72%). 
By as-treated analysis, excluding missing values, the proportions of patients with HIV RNA <400 copies/ml (<50 copies/ml) for REYATAZ + ritonavir were 84% (72%) and for lopinavir + ritonavir were 82% (72%).
* I en kombineret analyse af flere kliniske studier, hvor samtidig administration af atazanavir/ritonavir 300/100 mg og tenofovirdisoproxilfumarat 300 mg (n=39) blev sammenlignet med atazanavir/ritonavir 300/100 mg (n=33). 
* In a combined analysis from several clinical studies, atazanavir/ritonavir 300/100 mg co-administered with tenofovir disoproxil fumarate 300 mg (n=39) was compared to atazanavir/ritonavir 300/100 mg (n=33).
Hvis en højere dosis H2-receptorantagonist er nødvendig (f.eks. famotidin 40 mg 2 gange dagligt eller tilsvarende), kan dosisøgning af REYATAZ/ritonavir fra 300/100 mg til 400/100 mg overvejes. 
If a higher dose of an H2-receptor antagonist is required (e.g., famotidine 40 mg twice daily or equivalent) an increase of the REYATAZ/ritonavir dose from 300/100 mg to 400/100 mg can be considered.
REYATAZ bør ikke anvendes i kombination med lægemidler, der er CYP3A4-substrater, og som har et snævert terapeutisk indeks. 
REYATAZ should not be used in combination with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic index.
CD4-celletal <50 celler/mm3 
CD4 count <50 cells/mm3
Voriconazol AUC ↑561% (↑451% Voriconazol Cmax ↑438% (↑355% Voriconazol Cmin ↑765% (↑571% 
Voriconazole AUC ↑561% (↑451% Voriconazole Cmax ↑438% (↑355% Voriconazole Cmin ↑765% (↑571%
De farmakokinetiske data fra hiv-smittede gravide kvinder, der fik REYATAZ kapsler med ritonavir, er beskrevet i Tabel 8. 
The pharmacokinetic data from HIV-infected pregnant women receiving REYATAZ capsules with ritonavir are presented in Table 8.
Der er rapporteret alvorligt hududslæt, herunder Stevens-Johnsons syndrom (se afsnit 4), hos patienter, der tager REYATAZ. 
Serious skin rash, including Stevens-Johnson syndrome, has been reported in patients taking REYATAZ.
Sådan skal du tage REYATAZ 
How to take REYATAZ
Samtidig administration af REYATAZ med regimer der indeholder voxilaprevir frarådes. 
Co-administration of REYATAZ with voxilaprevir-containing regimens is not recommended.
Barnet kan mades med mere modermælkserstatning, væske eller føde efter indgivelse af hele blandingen. 
Additional infant formula, beverage or food may be given after consumption of the entire mixture.
Når rifabutin gives sammen med REYATAZ/ritonavir, er den anbefalede rifabutindosis 150 mg 3 gange ugentligt på fastsatte dage (for eksempel mandag-onsdag-fredag). 
When given with REYATAZ/ritonavir, the recommended dose of rifabutin is 150 mg 3 times per week on set days (for example MondayWednesday-Friday).
Kropsvægt og niveauerne af lipid og glucose i blodet kan stige under antiretroviral behandling (se pkt. 
Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4).
ikke almindelig: torsades de pointesa sjælden: QTc-forlængelsea, ødem, palpitation 
uncommon: torsades de pointesa rare: QTc prolongationa, oedema, palpitation
Hvis du føler dig svimmel eller uklar, må du ikke køre bil eller betjene maskiner, og du skal straks kontakte lægen. 
Driving and using machines If you feel dizzy or lightheaded, do not drive or use machines, and contact your doctor immediately.
*Interval på 70-143%, hvor der ikke er farmakokinetisk interaktion 
*Lack of pharmacokinetics interaction bounds 70-143%
REYATAZ/ritonavir bør ikke anvendes i kombination med lægemidler, der er CYP3A4-substrater, og som har et snævert terapeutisk indeks. 
REYATAZ/ritonavir should not be used in combination with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic index.
Koncentrationer af disse antiarytmika kan øges ved samtidig administration af REYATAZ. 
Concentrations of these antiarrhythmics may be increased when co-administered with REYATAZ.
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE TEKST PÅ YDRE ÆSKE 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON TEXT
Barnet skal drikke blandingen. 
The child is to drink the mixture.
Kontakt lægen, før du giver denne medicin til dit barn, hvis lægen har fortalt dig, at din barn ikke tåler visse sukkerarter. 
If you have been told by your doctor that your child has an intolerance to some sugars, contact your doctor before giving this medicinal product to your child.
Samtidig administration af REYATAZ med disse lægemidler forventes at øge deres koncentration væsentligt og kan resultere i PDE5-relaterede bivirkninger såsom hypotension, synsforstyrrelser og priapisme (se pkt. 
Co-administration of REYATAZ with these medicinal products is expected to substantially increase their concentrations and may result in PDE5-associated adverse reactions such as hypotension, visual changes and priapism (see section 4.5).
Inden blanding bankes der let på brevet for at samle pulveret. 
Prior to mixing, the sachet is tapped to settle the powder.
Tilsæt en ekstra spiseskefuld mad, rør rundt og mad barnet igen. 
Add an additional tablespoon in the container, mix and feed to your child again.
Man bør udvise særlig forsigtighed, når REYATAZ ordineres samtidig med lægemidler, som kan forøge QT-intervallet og/eller til patienter med allerede eksisterende risikofaktorer (bradykardi, medfødt langt QT, elektrolytforstyrrelser (se pkt. 
Particular caution should be used when prescribing REYATAZ in association with medicinal products which have the potential to increase the QT interval and/or in patients with preexisting risk factors (bradycardia, long congenital QT, electrolyte imbalances (see sections 4.8 and 5.3).
Didanosin skal tages fastende, 2 timer efter indtagelse af REYATAZ/ritonavir, taget til et måltid. 
Didanosine should be taken at the fasted state 2 hours after REYATAZ/ritonavir taken with food.
Øget overvågning for rifabutinassocierede bivirkninger inklusive neutropeni og uveitis er påkrævet pga. en forventet øget rifabutineksponering. 
Increased monitoring for rifabutin-associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to rifabutin.
hiv-RNA <50 kopier/ml, %a mindst 5 til < 10 kg (REYATAZ 150 og 200 mg) mindst 10 til < 15 kg mindst 15 til < 25 kg mindst 25 til < 35 kg hiv-RNA <400 kopier/ml, %a mindst 5 til < 10 kg (REYATAZ 150 og 200 mg) mindst 10 til < 15 kg mindst 15 til < 25 kg mindst 25 til < 35 kg 
HIV RNA <50 copies/ml, %a at least 5 to < 10 kg (REYATAZ 150 and 200 mg) at least 10 to < 15 kg at least 15 to < 25 kg at least 25 to < 35 kg
Carbamazepin bør anvendes med forsigtighed sammen med REYATAZ. 
Carbamazepine should be used with caution in combination with REYATAZ.
Samtidig brug af REYATAZ og fluticason, eller andre glukokortikoider, som metaboliseres af CYP3A4, frarådes, medmindre de potentielle fordele ved behandlingen opvejer risikoen for systemiske bivirkninger forårsaget af kortikosteroider, herunder Cushings syndrom og binyrebarksuppression (se pkt. 
Concomitant use of REYATAZ/ritonavir and fluticasone or other glucocorticoids that are metabolised by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression (see section 4.5).
Ved administration sammen med tenofovirdisoproxilfumarat anbefales det at give REYATAZ 300 mg med ritonavir 100 mg og tenofovirdisoproxilfumarat 300 mg (alle som en enkeltdosis sammen med mad). 
When co-administered with tenofovir disoproxil fumarate, it is recommended that REYATAZ 300 mg be given with ritonavir 100 mg and tenofovir disoproxil fumarate 300 mg (all as a single dose with food).
Lav ritonavirdosis (100 mg 2 gange dagligt) er vist ikke at have signifikant effekt på methadon-koncentrationen, og på baggrund af disse data forventes ingen interaktion ved samtidig administration af methadon og REYATAZ. 
Given that low dose ritonavir (100 mg twice daily) has been shown to have no significant effect on methadone concentrations, no interaction is expected if methadone is coadministered with REYATAZ, based on these data.
Dosis af REYATAZ-kapsler til børn beregnes ud fra barnets vægt og skal tages en gang dagligt sammen med mad og 100 mg ritonavir som vist i tabellen nedenfor: 
The dose of REYATAZ capsules for children is calculated by body weight and is taken once daily with food and 100 mg ritonavir as shown below:
Når rifabutin gives sammen med REYATAZ, er den anbefalede rifabutindosis 150 mg 3 gange ugentligt på fastsatte dage (for eksempel mandag-onsdagfredag). 
When given with REYATAZ, the recommended dose of rifabutin is 150 mg 3 times per week on set days (for example Monday-Wednesday-Friday).
Stik spidsen af sprøjten ned i blandingen og træk stemplet tilbage, indtil den nødvendige mængde modermælkserstatning er trukket op i sprøjten. 
Put the syringe tip into the mixture and pull back the plunger until the full amount of infant formula is taken up.
Samtidig administration af quetiapin og REYATAZ er kontraindiceret, da REYATAZ kan øge quetiapin-relateret toksicitet. 
Co-administration of quetiapine with REYATAZ is contraindicated as REYATAZ may increase quetiapine-related toxicity.
Dosis og det nødvendige antal breve med REYATAZ oralt pulver er baseret på legemsvægten (se pkt. 
The dose and the number of REYATAZ oral powder sachets needed is determined based on weight (see section 4.2.
Blandt patienter, der fik REYATAZ 400 mg, én gang dagligt, eller REYATAZ 300 mg med 100 mg ritonavir, én gang dagligt, var de eneste meget almindelige bivirkninger, af nogen sværhedsgrad og med mindst en mulig forbindelse til regimer indeholdende REYATAZ og én eller flere NRTIer: kvalme (20%), diarré (10%) og gulsot (13%). 
Among patients who received REYATAZ 400 mg once daily or REYATAZ 300 mg with ritonavir 100 mg once daily, the only adverse reactions of any severity reported very commonly with at least a possible relationship to regimens containing REYATAZ and one or more NRTIs were nausea (20%), diarrhoea (10%), and jaundice (13%).
PDE5-hæmmere ved behandling af erektil dysfunktion: Der bør udvises særlig forsigtighed ved ordinering af PDE5-hæmmere (sildenafil, tadalafil eller vardenafil) til behandling af erektil dysfunktion hos patienter, der får REYATAZ. 
PDE5 inhibitors used for the treatment of erectile dysfunction: particular caution should be used when prescribing PDE5-inhibitors (sildenafil, tadalafil, or vardenafil) for the treatment of erectile dysfunction in patients receiving REYATAZ.
Hæld yderligere 10 ml tilberedt modermælkserstatning i koppen eller beholderen for at skylle det resterende REYATAZ oralt pulver ud af koppen. 
Put another 10 ml of prepared infant formula in the cup or container and rinse the remaining oral powder from the cup or container.
Hvis du føler dig svimmel eller uklar, må du ikke køre bil eller betjene maskiner og du skal straks kontakte lægen. 
Driving and using machines If you feel dizzy or lightheaded, do not drive or use machines and contact your doctor immediately.
CD4 Middelændring fra baseline, celler/mm3 Alle patienter 
CD4 Mean Change from Baseline, cells/mm3 All patients
d Intent-to-treat-analyse hvor manglende værdier anses som svigt. 
d Intent-to-treat analysis, with missing values considered as failures.
PDE5-hæmmere ved behandling af erektil dysfunktion: Der bør udvises særlig forsigtighed ved ordinering af PDE5-hæmmere (sildenafil, tadalafil eller vardenafil) til behandling af erektil dysfunktion hos patienter, der får REYATAZ samtidig med lavdosis ritonavir. 
PDE5 inhibitors used for the treatment of erectile dysfunction: particular caution should be used when prescribing PDE5-inhibitors (sildenafil, tadalafil, or vardenafil) for the treatment of erectile dysfunction in patients receiving REYATAZ with concomitant low-dose ritonavir.
Se også PULMONAL ARTERIEL HYPERTENSION i denne tabel for yderligere information om samtidig administration af REYATAZ/ritonavir og sildenafil. 
Also see PULMONARY ATERIAL HYPERTENSION in this table for further information regarding co-administration of REYATAZ/ritonavir with sildenafil.
REYATAZ med ritonavir bør anvendes med forsigtighed til patienter med let nedsat leverfunktion. 
REYATAZ with ritonavir should be used with caution in patients with mild hepatic impairment.
HCV-proteasehæmmere 
HCV Protease Inhibitors
* Sammenlignet med REYATAZ 300 mg/ritonavir 100 mg én gang dagligt om aftenen uden efavirenz. 
* When compared to REYATAZ 300 mg/ritonavir 100 mg once daily in the evening without efavirenz.
Hvis REYATAZ administreres samtidig med irinotecan, bør patienten monitoreres tæt for irinotecan-relaterede bivirkninger. 
If REYATAZ is co-administered with irinotecan, patients should be closely monitored for adverse events related to irinotecan.
Galdeblæreproblemer kan forekommme mindre hyppigt hos personer, der tager REYATAZ. 
Gallbladder problems uncommonly happen in people taking REYATAZ.
Der er set reversible forhøjelser i indirekte (ukonjugeret) bilirubin relateret til hæmning af UDPglucuronosyltransferase (UGT) hos patienter i behandling med REYATAZ (se pkt. 
Reversible elevations in indirect (unconjugated) bilirubin related to inhibition of UDP-glucuronosyl transferase (UGT) have occurred in patients receiving REYATAZ (see section 4.8).
REYATAZ kapsler fås til pædiatriske patienter, som er mindst 6 år og vejer mindst 15 kg og er i stand til at sluge kapsler (se produktresumeet for REYATAZ kapsler). 
REYATAZ capsules are available for paediatric patients at least 6 years of age who weigh at least 15 kg and who are able to swallow capsules (see Summary of Product Characteristics for REYATAZ
LÆGEMIDDELFORM OG ANTAL (PAKNINGSSTØRRELSE) Oralt pulver 
PHARMACEUTICAL FORM AND CONTENTS Oral Powder
Dosisjustering er ikke nødvendig for REYATAZ/ritonavir og fluconazol. 
No dosage adjustments are needed for REYATAZ/ritonavir and fluconazole.
Didanosin skal tages fastende, 2 timer efter indtagelse af REYATAZ, taget til et måltid. 
Didanosine should be taken at the fasted state 2 hours after REYATAZ taken with food.
Benzodiazepiner 
SEDATIVES Benzodiazepines
Andelen af patienter med hiv-RNA <400 kopier/ml (< 50 kopier/ml) i REYATAZ + ritonavir-armen og lopinavir + ritonavir-armen var henholdsvis 55% (40%) og 56% (46%). 
By as-treated analysis, excluding missing values, the proportions of patients with HIV RNA < 400 copies/ml (< 50 copies/ml) in the REYATAZ + ritonavir arm and the lopinavir + ritonavir arm were 55% (40%) and 56% (46%), respectively.
Samtidig administration af REYATAZ og lægemidler, der inducerer CYP3A4 frarådes (se pkt. 
Co-administration of REYATAZ and medicinal products that induce CYP3A4 is not recommended (see sections 4.3 and 4.5).
Seks ud af 20 (30%) kvinder, der fik REYATAZ/ritonavir 300/100 mg og 13 ud af 21 (62%) kvinder, der fik REYATAZ/ritonavir 400/100 mg oplevede grad 3 til 4 hyperbilirubinæmi. 
Six of 20 (30%) women on REYATAZ/ritonavir 300/100 mg and 13 of 21 (62%) women on REYATAZ/ritonavir 400/100 mg experienced grades 3 to 4 hyperbilirubinaemia.
Pædiatriske studier med REYATAZ oralt pulver 
Paediatric trials with REYATAZ oral powder
REYATAZ oralt pulver skal tages sammen med ritonavir og i forbindelse med et måltid. 
REYATAZ oral powder must be taken with ritonavir and has to be taken with food.
Vælg en af nedenstående måder, hvorpå du kan give dit barn REYATAZ oralt pulver. 
Choose the appropriate option listed below for giving REYATAZ oral powder to your child.
REYATAZ en daglig dosis (mg) 
REYATAZ Dose once daily (mg)
Anbefalet dosis REYATAZ-kapsler er 300 mg én gang dagligt sammen med 100 mg ritonavir én gang dagligt og i forbindelse med et måltid. 
The recommended dose of REYATAZ capsules is 300 mg once daily taken with ritonavir 100 mg once daily and with food.
Den hyppigst rapporterede laboratoriemæssige anormalitet hos pædiatriske patienter i behandling med REYATAZ var forhøjet total-bilirubin (≥ 2,6 gange ULN, grad 3-4), som forekom hos 45% af patienterne. 
The most frequently reported laboratory abnormality in paediatric patients receiving REYATAZ was elevation of total bilirubin (≥ 2.6 times ULN, Grade 3-4) which occurred in 45% of patients.
Quinidin har et snævert terapeutisk indeks og er kontraindiceret pga. risiko for CYP3Ahæmning med REYATAZ/ritonavir. 
Quinidine has a narrow therapeutic window and is contraindicated due to potential inhibition of CYP3A by REYATAZ/ritonavir.
Hele blandingen trækkes op i en mundsprøjte og indgives enten i barnets højre eller venstre kindhule. 
The full amount of the mixture is drawn up into an oral syringe and administered into either right or left inner cheek of the infant.
Få barnet til at drikke blandingen. 
Have the child drink the mixture.
Koncentrationer af disse antiarytmika kan øges ved samtidig administration af REYATAZ/ritonavir. 
Concentrations of these antiarrhythmics may be increased when co-administered with REYATAZ/ritonavir.
Dosisjustering er ikke nødvendig for fluconazol og REYATAZ. 
No dosage adjustments are needed for fluconazole and REYATAZ.
REYATAZ med ritonavir har ikke været undersøgt hos patienter med nedsat leverfunktion. 
REYATAZ with ritonavir has not been studied in patients with hepatic impairment.
Råhvidt til lysegult pulver. 
Off white to pale yellow powder.
NAVN PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN BRISTOL-MYERS SQUIBB PHARMA EEIG 3. 
NAME OF THE MARKETING AUTHORISATION HOLDER BRISTOL-MYERS SQUIBB PHARMA EEIG
Brug ikke lægemidlet efter den udløbsdato, der står på æsken eller brevet efter Exp. Udløbsdatoen er den sidste dag i den nævnte måned. 
Do not use this medicine after the expiry date which is stated on the carton or sachet.
Interaktionsmekanismen er nedsat opløselighed af atazanavir pga. intragastrisk pH-stigning med H2blokkere. 
The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with H2blockers.
(n=90e) 
(n=90
Sjældne (kan forekomme hos op til 1 ud af 1.000 personer): gangforstyrrelser væskeophobninger forstørrelse af lever og milt muskelsmerter og muskelømhed på grund af svaghed, der ikke er forårsaget af motion nyresmerter 
Rare (may affect up to 1 in 1,000 people): gait disturbance (abnormal manner of walking) oedema (swelling) hepatosplenomegaly (enlargement of the liver and spleen) myopathy (aching muscles, muscle tenderness of weakness, not caused by exercise) kidney pain
* Sammenlignet med REYATAZ 300 mg/ritonavir 100 mg uden nevirapin. 
* When compared to REYATAZ 300 mg and ritonavir 100 mg without nevirapine.
Atazanavir- og fluconazolkoncentrationerne ændredes ikke signifikant ved samtidig administration af REYATAZ/ritonavir og fluconazol. 
Atazanavir and fluconazole concentrations were not significantly modified when REYATAZ/ritonavir was co-administered with fluconazole.
* Atazanavir 300 mg og ritonavir 100 mg (n=33) er i en kombineret analyse sammenlignet med atazanavir 400 mg uden ritonavir (n=28). 
* In a combined analysis, atazanavir 300 mg and ritonavir 100 mg (n=33) was compared to atazanavir 400 mg without ritonavir (n=28).
Der er ikke fastlagt en sikker og effektiv dosis for sildenafil i kombination med REYATAZ til behandling af pulmonal arteriel hypertension. 
A safe and effective dose in combination with REYATAZ has not been established for sildenafil when used to treat pulmonary arterial hypertension.
Af hensyn til miljøet må du ikke smide medicinrester i afløbet, eller toilettet eller skraldespanden. 
Do not throw away any medicines via wastewater or household waste.
hiv-RNA <50 kopier/ml ved selekteret baseline PI-substitution,c % (respondent/evaluerbard) 
HIV RNA <50 copies/ml by select baseline PI substitutions,c % (responder/evaluabled) NA
Desacetyl-diltiazem Cmin ↑121% 
Desacetyl-diltiazem AUC ↑165% Desacetyl-diltiazem Cmax ↑172% Desacetyl-diltiazem Cmin ↑121%
Hjælpestof, som behandleren skal være opmærksom på: 82,18 mg lactose per kapsel. 
Excipient with known effect: 82.18 mg of lactose per capsule.
15 til under 35 mindst 35 
15 to less than 35 at least 35
Efter opblanding med mad eller drikke, kan blandingen opbevares i op til 1 time ved stuetemperatur (ikke over 30°C). 
After mixing the oral powder with food or drinks, it may be stored at room temperature (not above 30oC) for up to 1 hour.
Hvis REYATAZ/ritonavir administreres samtidig med irinotecan, bør patienten monitoreres tæt for irinotecanrelaterede bivirkninger. 
If REYATAZ/ritonavir is coadministered with irinotecan, patients should be closely monitored for adverse events related to irinotecan.
50 to <100 celler/mm3 
50 to <100 cells/mm3
Patienterne bør advares om risikoen for disse bivirkninger ved brug af PDE5-hæmmere mod erektil dysfunktion samtidig med REYATAZ (se pkt. 
Patients should be warned about these possible side effects when using PDE5 inhibitors for erectile dysfunction with REYATAZ (see section 4.4).
Da REYATAZ hæmmer CYP3A4, forventes koncentrationen af quetiapin at stige. 
Due to CYP3A4 inhibition by REYATAZ, concentrations of quetiapine are expected to increase.
Administration sammen med REYATAZ/ritonavir kan medføre en stor stigning i koncentrationen af disse benzodiazepiner. 
Co-administration with REYATAZ/ritonavir may cause a large increase in the concentration of these benzodiazepines.
For instruktioner om klargøring og administration af REYATAZ oralt pulver og brugsvejledning, se pkt. 
For details on preparation and administration of the REYATAZ oral powder and Instructions for Use, see section 6.6.
Der er rapporteret om hududslæt og kløe, som i nogle tilfælde kan være alvorligt. 
Skin rash, itching that may occasionally be severe has been reported.
Gennemsnitlig halveringstid var, inden for atazanavirs dosisinterval, hos hiv-inficerede voksne patienter (n=33, kombinerede studier) 12 timer ved steady state efter en dosis på 300 mg dagligt med 100 mg ritonavir én gang dagligt med et let måltid. 
In HIV-infected adult patients (n=33, combined studies) the mean half-life within a dosing interval for atazanavir was 12 hours at steady state following a dose of 300 mg daily with ritonavir 100 mg once daily with a light meal.
Hjælpestof, som behandleren skal være opmærksom på: 164,36 mg lactose per kapsel. 
Excipient with known effect: 164.36 mg of lactose per capsule.